China Pharmaceutical University

Shanghai, China – June 9, 2026 – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. (“Vcare PharmaTech”), for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China. Pursuant to the agreement, Everest Medicines will pay Vcare PharmaTech an upfront payment of RMB 20 million, along with subsequent milestone payments and commercial supply procurement. This collaboration strengthens the Company’s cardiovascular portfolio and highlights Everest’s continued focus on the Asia-Pacific market, supporting the advancement of its regional strategy and the development of innovative therapies. Sumecigrel is an antiplatelet agent and a new-generation oral P2Y12 receptor antagonist. It is being clinically developed for the treatment and prevention of atherothrombotic events such as acute coronary syndrome (ACS), ischemic stroke (IS) and peripheral arterial disease (PAD). As a novel antithrombotic drug developed by Vcare PharmaTech, the product is currently advancing preparations for NDA in China, the United States, Europe. The molecular design of Sumecigrel targets the black box warning associated with clopidogrel resistance. It innovatively optimizes the metabolic pathway of clopidogrel while retaining its active metabolite, striking a better balance between therapeutic benefits and bleeding risks inherent to antiplatelet medications. Featuring faster onset of action, lower dosage, more stable efficacy, better controllable bleeding risks, reduced metabolic burden and broader clinical applicability, Sumecigrel is a novel antiplatelet candidate with prominent Best-in-Class potential. It is expected to address the increasingly personalized demands for antithrombotic therapy and become a blockbuster product in the antithrombotic market. “This collaboration with Vcare PharmaTech marks another step in strengthening our presence in the Asia-Pacific region,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Sumecigrel is a next-generation oral P2Y12 receptor antagonist with Best-in-Class potential, offering differentiated clinical benefits and complementing Everest’s cardiovascular pipeline. Leveraging our clinical, regulatory, and commercial capabilities across the Asia-Pacific as a global platform for innovative therapies, Everest will drive Sumecigrel’s development and commercialization to realize its full clinical and commercial value and bring new treatment options to more patients.” "As our novel antithrombotic drug, Sumecigrel represents our first innovative pharmaceutical product, "said Dr. Gong Yanchun, Co-founder, Chairman and CEO of Vcare PharmaTech. "This strategic partnership with Everest Medicines serves as the first step of Sumecigrel’s global commercialization strategy, creating a win-win situation for an original innovation enterprise and an international commercial platform. Powered by AI-driven differentiated original design, Vcare PharmaTech consistently focuses on the development of innovative drugs and leading therapies, standing as a pioneer of the next-generation original innovation in the global antiplatelet field. We will accelerate the global R&D and registration progress of Sumecigrel, consolidate its global competitive edges, and contribute Chinese innovation to the diagnosis and treatment of cardiovascular diseases across the Asia-Pacific and the world at large." Cardio-cerebrovascular diseases rank among the leading causes of death worldwide. Related fatalities rose sharply to 17.9 million in 2019, accounting for approximately 32% of all global deaths. Around 85% of these deaths were attributed to myocardial infarction (a major type of ACS) and stroke. The death toll from cardio-cerebrovascular diseases further climbed to 19.2 million in 2023. Antiplatelet drugs inhibit platelet activation, adhesion and aggregation to reduce thrombotic risks, and are widely used for the prevention and treatment of atherothrombotic diseases. P2Y12 receptor antagonists are a major category of mainstream antiplatelet medications. Currently marketed products in this class continue to face challenges in balancing variability in efficacy and bleeding risk across patients, and optimizing the overall clinical benefit–risk profile remains an important unmet medical need in this therapeutic area. As a next-generation P2Y12 receptor antagonist, Sumecigrel has completed Phase I, Phase II, China-US PK/PD bridging study and Phase III clinical trials. It has demonstrated favorable efficacy and safety with solid clinical value, and is poised to become an improved treatment option for patients with ACS, IS and PAD. About Sumecigrel Sumecigrel is the world’s first new-generation P2Y12 receptor antagonist designed to resolve clopidogrel’s heavy reliance on CYP2C19 genetic polymorphism by optimizing its metabolic pathway while retaining clopidogrel’s active metabolite. It is indicated for atherothrombotic events including acute coronary syndrome, ischemic stroke and peripheral arterial disease. It stands as one of Vcare PharmaTech’s flagship achievements underpinned by the philosophy of differentiated original design to tackle unmet clinical needs. Its molecular design findings were published in Journal of Medicinal Chemistry (JMC), a top journal of the American Chemical Society, and highlighted by SciBX under Nature Portfolio, which recognized it as one of the most commercially promising projects in the field of novel drugs. Currently in preparation for NDA submissions in multiple countries, Sumecigrel possesses strong Best-in-Class potential and broad commercial prospects, and is expected to reshape the antithrombotic market where no new innovative drugs targeting the same mechanism have been launched for over a decade. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com. About Vcare PharmaTech Founded in 2010 by professors from China Pharmaceutical University and overseas returnee talents, Vcare PharmaTech is a commercial-stage innovative biopharmaceutical enterprise adopting AI-enabled differentiated original drug design and dedicated to developing innovative drugs and leading therapies. The Company has built a full-spectrum innovation system covering the entire R&D and industrialization lifecycle of new drugs, from AI-powered differentiated project initiation and preclinical candidate discovery to integrated pharmaceutical development and green manufacturing. It houses the Nanjing Key Laboratory for AI-Driven Drug Design and Nanjing Engineering Research Center for Synthetic Biology and Flow Chemistry. Focused on addressing unmet clinical demands via differentiated approaches, Vcare PharmaTech develops a tiered, high-quality and diversified pipeline of innovative drugs targeting treatment resistance, drug resistance and targeted selectivity optimization. Its product portfolio covers major chronic disease areas including inflammation and autoimmunity, cardio-cerebrovascular diseases and oncology, striving to deliver superior treatment solutions for patients worldwide. For more information, please visit www.vcarepharmatech.com. Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

SHANGHAI, June 7, 2026 /PRNewswire/ -- OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") , announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administration (NMPA) to proceed into a confirmatory Phase II clinical trial in patients with GPC3-positive advanced hepatocellular carcinoma (HCC). The study is designed as a prospective, randomised, open-label, multi-centre registration trial evaluating the efficacy and safety of Ori-C101 in patients who have failed two or more prior lines of therapy. This marks the first GPC3-directed immune cell therapy anywhere in the world to enter a confirmatory trial, and the first CAR-T product for a liver cancer indication to reach a Phase II randomised controlled study — a milestone that underscores China's potential to lead the next wave of innovation in cell therapy for solid tumours. HCC, a disease with few options at the late line Hepatocellular carcinoma is among the most prevalent malignancies globally, with China alone accounting for roughly 410,000 new cases and 317,000 deaths each year. For patients whose disease has progressed through both immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI), options are essentially exhausted: existing second-line agents were developed for patients intolerant of, or progressing on, first-line sorafenib, and nothing has been approved beyond that point. The unmet need is acute. Phase I data of Ori-C101: robust efficacy and manageable safety Results from the Phase I BEACON study were featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which recently wrapped up in Chicago, drawing significant attention from the oncology community. All enrolled patients had failed at least two prior lines of therapy, including both TKI and ICI treatment. Key results: Objective response rate (ORR): 50% across the evaluable population; 66.7% in the recommended Phase II dose (RP2D) cohort; 100% in the highest dose cohort (DL4) Speed of response: 89% of responders had already achieved objective response by their first post-infusion assessment, with marked tumour shrinkage Overall survival (OS): Median OS of 21.4 months in the overall population; 12-month survival rate of 69.3% — more than double the roughly 10.6-month historical median seen with available second-line agents, heralding a potential new era of long-term survival for patients with advanced HCC Safety: Cytokine release syndrome (CRS) was manageable; no immune effector cell-associated neurotoxicity syndrome (ICANS) or off-target toxicity was observed, and tolerability was favourable across the study population Notable case: One patient achieved partial response at first assessment, progressed to complete response by month four, and remains in remission at 24 months Mechanism and broader potential GPC3 (Glypican-3) is overexpressed in more than 70% of hepatocellular carcinomas, as well as in gastric cancer, lung squamous cell carcinoma, and ovarian clear cell carcinoma — making it a highly specific and compelling target for cancer therapy. Ori-C101 is engineered to identify and eliminate GPC3-positive tumour cells with precision, drawing on two proprietary platforms: Ori®Ab (AI-assisted antibody discovery and engineering) and Ori®Armoring (structure-enhanced cell platform). Ori-C101's profile has the potential to support use in earlier lines of treatment, and GPC3's expression across multiple tumour types provides a strong scientific rationale for future indication expansion. As the confirmatory trial advances, the goal of treatment in advanced HCC has the potential to shift from controlling disease to achieving durable remission — or even cure. Principal investigators The confirmatory Phase II study is a nation-wide, multi-centre trial co-led by Professor Fan Jia (Academician of the Chinese Academy of Sciences and Honorary President of Zhongshan Hospital, Fudan University) and Professor Qin Shukui (Qiantang Scholar and Professor at Nanjing Tianyinshan Hospital, China Pharmaceutical University). In a joint statement, the two investigators said: "In our earlier work on late-line advanced HCC, the BEACON study delivered important progress. GPC3 is specifically overexpressed in HCC and represents an ideal therapeutic target, yet GPC3-directed CAR-T approaches have historically been constrained by the immunosuppressive tumour microenvironment. BEACON was designed precisely to break through that barrier and find a new, accessible path for patients who have exhausted their options. The preliminary results from this novel 'armoured' GPC3 CAR-T construct — showing strong objective response rates with a manageable safety profile — not only address an evidence gap in late-line refractory HCC but offer broader lessons for innovative immune cell therapies in solid tumours. We look forward to the Phase II randomised controlled study, and to obtaining the expected results under rigorous scientific design, comprehensive management, and strict quality control." OriCell co-founder, Chairman and Chief Executive Officer Dr. Yang Huanfeng commented: "We are deeply grateful to the NMPA Centre for Drug Evaluation and relevant government authorities for their strong support of innovative drug development, and to Academician Fan, Professor Qin and their teams for their trust and active participation. This approval validates the scientific soundness and feasibility of our technology platform and marks a new stage of growth for OriCell. With a clear regulatory pathway now in place, we will push forward with Ori-C101's confirmatory clinical development, with the aim of bringing a genuinely new treatment option to patients as quickly as we can. We believe this progress will also underpin China's strategy for taking innovative medicines global and competing actively in international markets." About OriCell Therapeutics OriCell Therapeutics is a clinical-stage, globally oriented biotechnology company committed to pioneering cancer immunotherapy. Focused on addressing unmet medical needs in oncology and immunology, the company has built a robust pipeline spanning both solid and haematological tumours, powered by three proprietary technology engines: Ori®AB (AI-assisted antibody discovery and engineering), Ori®Armoring (structure-enhanced cell platform), and Ori®OnGo (classic, rapid, and in vivo manufacturing platform). The company's clinical translation capabilities have earned broad international recognition, with multiple data readouts selected for oral presentations at leading conferences including ASCO and EHA, and published in top-tier journals such as The Lancet Haematology. OriCell is accelerating its global expansion, driven by a commitment to continuous innovation and the ambition to bring new hope to cancer patients worldwide. For more information, please visit . Forward-Looking Statements This press release contains forward-looking statements. These statements are not historical facts, but rather predictions about future events based on the beliefs, assumptions, and information currently available to the management of OriCell Therapeutics Holdings Limited (the "Company"). Words and phrases such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Such statements involve known and unknown risks, uncertainties, and other important factors that could cause the Company's actual results, performance, or achievements to differ materially from those expressed or implied. Any forward-looking statements contained in this press release speak only as of the date of this release. The Company wishes to clarify that this announcement is intended solely to communicate research and clinical development progress, is for reference by healthcare professionals only, is not promotional in nature, and does not constitute a recommendation for the use of any unapproved drug or indication. SOURCE Oricell Therapeutics Holdings Limited 21% more press release views with Request a Demo

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, more than 229 fusion partner genes have been discovered, giving rise to 358 unique fusion-tumor pairings. Patients harboring such fusions generally have a poor prognosis. For advanced solid tumor patients who do not receive targeted therapy, the median overall survival ranges from 10.2 to 12.7 months, and these patients are also at a higher risk of brain metastasis. Meanwhile, the loss of the extracellular domain in NTRK fusions renders antibody-based therapies ineffective. Currently, treatment primarily relies on small-molecule TRK inhibitors that target the kinase domain.1-3 Continue Reading Vcare PharmaTech Innovative Drug Pipeline In terms of tumor type distribution, NTRK fusions are characterized by rare mutations with broad tumor spectrum distribution. On one hand, the incidence of NTRK fusions reaches up to 90% in rare malignancies such as secretory breast carcinoma and infantile fibrosarcoma, and ranges from 5% to 25% in papillary thyroid carcinoma and Spitzoid melanoma. On the other hand, real-world data from approximately 295,000 solid tumor patients worldwide indicate that NTRK fusion-positive cases account for a larger absolute number of patients among common cancer types. Collectively, NTRK fusion-positive patients with non-small cell lung cancer, breast cancer, soft tissue sarcoma and colorectal cancer make up nearly 50% of all affected cases, representing the key population requiring close clinical attention. In addition, the prevalence of NTRK fusions is higher in East Asian populations, with an overall incidence of approximately 0.4% among Chinese patients. It is estimated that more than 15,000 new cases of NTRK fusion-positive solid tumors are diagnosed in China each year.4-5 Breaking News: Domestic Next-Generation Tumor-Agnostic Targeted Drug Eratrectinib Approved On June 4, the official website of the NMPA announced that Vcare PharmaTech's Class 1 new drug, Eratrectinib, has been approved for marketing in China. It is indicated for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions. Efficacy Breakthrough: Eratrectinib Delivers Comprehensive Clinical Benefits Eratrectinib is a next-generation TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co.,Ltd.. In pivotal registration clinical trials for patients with NTRK fusion-positive solid tumors, this pan-tumor anticancer agent has demonstrated outstanding efficacy and safety. Registration study results showed an ORR of 68.5% and a DCR of 85.2%. Among patients followed up for more than 6 months, the ORR reached 89.7% and the DCR was 100%, with a mOS of 40.7 months.6 In terms of long-term clinical benefits, Eratrectinib also achieved impressive results in PFS and DOR. The 2-year PFS rate stood at 75.7% and the 2-year DOR rate hit 85.5%, fully proving that the drug can deliver sustained disease control and long-term remission for patients. Furthermore, for patients with baseline brain metastases, the ORR was as high as 87.5%. For patients previously treated with TRK-TKIs, the ORR reached 47.4%, reflecting robust therapeutic efficacy across these patient groups. New Hope for Patients with NTRK Fusion Resistance As a next-generation TRK inhibitor independently developed in China, Eratrectinib delivers durable and deep tumor remission, with potent brain penetration and a favorable overall safety profile. Different from the linear structure of first-generation TRK inhibitors, Eratrectinib features a cyclic molecular structure. Structural optimization reduces off-target risks and effectively prevents the emergence of drug-resistant mutations, endowing the agent with the anti-resistance mechanisms characteristic of second-generation TRK inhibitors. About Vcare PharmaTech Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) was co-founded in 2010 by professors from China Pharmaceutical University and overseas returnee experts. As a commercial-stage innovative biopharmaceutical enterprise empowered by AI for differentiated de novo drug design, the Company is dedicated to the development of novel medicines and cutting-edge therapeutics, and has been accredited as a National Key Specialized, Refined, Differential and Innovative "Little Giant" Enterprise. Headquartered in the Biotech and Pharmaceutical Valley of Nanjing Jiangbei New Area, Vcare PharmaTech owns an intelligent R&D headquarters spanning 21,000 square meters. It has built a full-chain innovation system covering independent new drug R&D and industrialization, ranging from AI-powered differentiated target initiation at the early discovery stage, preclinical candidate identification, integrated collaborative pharmaceutical development to green manufacturing. Boasting a robust talent pipeline, the Company employs over 900 staff members, among whom technical professionals account for more than 84%, including over 200 master's and doctoral degree holders. Such a highly educated, specialized and innovation-driven core R&D workforce underpins the Company's sustained technological breakthroughs and product upgrading. Having engaged in pharmaceutical innovation for 16 years, Vcare PharmaTech adheres to the core strategy of indigenous R&D and innovation, targeting unmet clinical needs via differentiated therapeutic approaches. Centered on addressing treatment resistance, overcoming drug resistance and improving target selectivity, the Company has established a high-quality, diversified and tiered innovative drug pipeline covering major chronic illnesses including cardiovascular and cerebrovascular diseases, inflammatory autoimmune disorders and oncology, with its novel pharmaceutical discoveries positioned for global commercialization. The Company's core pipeline candidates feature prominent competitive edges and promising commercial prospects. Eratrectinib (VC004), a next-generation TRK inhibitor and small-molecule targeted anti-tumor agent indicated for solid tumors driven by NTRK gene fusions, delivers tumor-agnostic therapeutic benefits across a broad spectrum of indications and has obtained marketing approval in China. Sumecigrel Capsule, a novel oral P2Y12 receptor antagonist selected four times for China's National Major Science and Technology Projects, precisely inhibits platelet activation and aggregation to block thrombosis for the prevention and treatment of cardiovascular, cerebrovascular and arterial circulatory disorders; its pivotal confirmatory clinical trials are well underway domestically. VC005, a new-generation highly selective JAK1 inhibitor, is being developed via both oral and topical formulations for full-population treatment of atopic dermatitis with all indications in Phase III clinical trials. The asset is also under clinical development for ankylosing spondylitis, vitiligo, alopecia areata and other autoimmune diseases, with robust efficacy and safety data accelerating its clinical progression. Backed by years of technological accumulation, the Company strives to integrate AI capabilities across the entire value chain from early R&D to manufacturing, establishing an AI-enabled premium innovative drug development system and specialized technical platforms. Its R&D platforms have been officially accredited as Nanjing Key Laboratory for AI-Assisted Drug Design and Nanjing Engineering Research Center for Synthetic Biology & Flow Chemistry; its AI-directed site-specific enzyme mutation technology has been recognized as Advanced Cleaner Production Technology by Nanjing authorities. Over the past five years, the Company has secured aggregate financing exceeding RMB 1.2 billion, earning strong recognition from the capital market. Moving forward, abiding by its founding mission of "The better Care, The better Medicines", Vcare PharmaTech will keep advancing AI-driven original innovation and cutting-edge pharmaceutical technologies while expanding its footprint across domestic and overseas markets. Leveraging robust R&D strengths to build a differentiated novel drug portfolio, the company commits to delivering superior therapeutic options for patients worldwide and evolving into a globally influential innovative pharmaceutical enterprise. References: Nguyen MA, et al. Pathology. 2023 Aug;55(5):596-609. Jiang T, et al. Acta Pharm Sin B. 2021 Feb;11(2):355-372. Cocco E, et al. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. O'Haire S, et al. Sci Rep. 2023 Mar 13;13(1):4116. Qi C, et al. Int J Cancer. 2023 Dec 1;153(11):1916-1927. Vcare Pharma. Phase II Clinical Study Data of Eratrectinib[R] Commercial Cooperation: Strategic Development Director: Dr. Peng, [email protected] BD Director: Liam, [email protected] SOURCE Vcare PharmaTech 21% more press release views with Request a Demo